Position
Fidelity in Xenon Pharmaceuticals Inc.
Back to the book · All holders of XENE
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $21.3M$58.15 → $60.36
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 8.92M | $399.8M | — | — | — | 0.0% |
| Q1 2026 | 10.8M | $629.1M | $58.15 | $118.9M | $110.4M | 0.0% |
| Q2 2026 | 9.65M | $582.4M | $60.36 | $21.3M | −$68.1M | 0.0% |